Investigation Into the Effects of Blood Glucose Levels Upon Eating Behavior in Lean and Obese Non-diabetic and Diabetic Subjects
8 de abril de 2022 atualizado por: Yale University
To investigate whether the daily glucose profiles as assessed by continuous glucose monitoring for 1 week of normal weight and obese individuals relate to hunger levels and food intake.
Visão geral do estudo
Status
Concluído
Condições
Intervenção / Tratamento
Descrição detalhada
To evaluate the effect of blood glucose levels on eating behavior in a population of patients with diabetes in a free-living environment; the investigators plan to study lean healthy control subjects (BMI <25 kg/m2) and obese non-diabetic subjects (BMI > 30 kg/m2).
The participants who qualify will be invited to use the CGMS (DEXCOM G4 Platinum) for up to 7 days. On the visit for placement of the CGMS: 1) the participants will be explained by one of the study physicians how to use a glucometer (FreeStyle or Accu-Check), 2) they will have the CGMS inserted under the skin, and 3) they will be instructed how to fill up the food log (informational brochures are available at the end of the protocol. On the second visit (up to 7 days after the initial visit) the CGMS will be removed from the skin and the glucose meter and food log will be returned to the investigators.
When this study was initially designed, it incorporated 2 additional arms in the study: T1DM and obese T2DM patients. These patients were never recruited for the study.
Tipo de estudo
Intervencional
Inscrição (Real)
31
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06520
- Yale University School Of Medicine
-
New Haven, Connecticut, Estados Unidos, 06519-1362
- Yale New Haven Hospital
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos a 65 anos (Adulto, Adulto mais velho)
Aceita Voluntários Saudáveis
Sim
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- A1c < 10.5 %
Exclusion Criteria:
- BMI <18 (no upper limit),
- Creatinine > 1.5 mg/dL,
- Hgb < 10 mg/dL,
- ALT > 2.5 X ULN,
- untreated thyroid disease,
- uncontrolled hypertension,
- known neurological disorders,
- untreated psychiatric disorders,
- use of antidepressants and psychiatric medications,
- use of weight loss medications in the 6 months prior to the study,
- malignancy,
- smoking,
- current or recent steroid use in last 3 months,
- history of current illicit drug use;
- for women: pregnancy, or breastfeeding.
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Diagnóstico
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Lean Healthy Control
(BMI <25 kg/m2)
|
The CGMS consists of 3 parts: sensor, transmitter and monitor.
The small sensor measures the glucose levels from the interstitial tissue.
The transmitter is attached on top of the sensor and connects wirelessly to the monitor.
The sensor is sterile and comes in an unopened package.
It has a plastic wire-like tip that is placed under the skin and continuously measures the glucose levels.
One of the study physicians will insert the CGMS wire-like tip under the volunteer's skin with the use of the DEXCOM sensor insertion kit.
The transmitter is snapped to the sensor pod and the sensor/transmitter unit will be attached to the skin with an adhesive patch.
The monitor is the size of a small hand-held device with a digital screen that displays a graph showing the glucose levels from the previous 4-24 hours.
Outros nomes:
The Food Record will ask about amount and type of food consumed throughout the day.
The participants will also register how hungry they are before the meal and how full they feel after they ate, and type and duration of physical activity
|
|
Comparador Ativo: Obese non-diabetic subject
BMI > 30 kg/m2
|
The CGMS consists of 3 parts: sensor, transmitter and monitor.
The small sensor measures the glucose levels from the interstitial tissue.
The transmitter is attached on top of the sensor and connects wirelessly to the monitor.
The sensor is sterile and comes in an unopened package.
It has a plastic wire-like tip that is placed under the skin and continuously measures the glucose levels.
One of the study physicians will insert the CGMS wire-like tip under the volunteer's skin with the use of the DEXCOM sensor insertion kit.
The transmitter is snapped to the sensor pod and the sensor/transmitter unit will be attached to the skin with an adhesive patch.
The monitor is the size of a small hand-held device with a digital screen that displays a graph showing the glucose levels from the previous 4-24 hours.
Outros nomes:
The Food Record will ask about amount and type of food consumed throughout the day.
The participants will also register how hungry they are before the meal and how full they feel after they ate, and type and duration of physical activity
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Rate of Changing Glucose Level
Prazo: 3-5 days
|
The CGM sensor measures the glucose levels from the interstitial tissue.
Presented is the rate of changing glucose level (mg/dl/min).
|
3-5 days
|
|
Glucose Peak
Prazo: 3-5 days
|
The CGM sensor measures the glucose levels from the interstitial tissue.
Presented is the glucose peak (mg/dl).
|
3-5 days
|
|
Glucose Nadir
Prazo: 3-5 days
|
The CGM sensor measures the glucose levels from the interstitial tissue.
Presented is the glucose nadir (mg/dl).
|
3-5 days
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Difference in Glucose Peak and Nadir
Prazo: 3-5 days
|
The CGM sensor measures the glucose levels from the interstitial tissue.
Presented is the difference in glucose peak and nadir (mg/dl).
|
3-5 days
|
|
Average Daily Hunger Rating
Prazo: 3-5 days
|
Average daily hunger was measured using a self-report scale.
Hunger is measured on a scale from 1-10. 10 is the most hungry, 1 is the least hungry.
|
3-5 days
|
|
Nutirion Intake: Energy
Prazo: 3-5 days
|
Data were collected through food journals.
Energy and macronutrient composition were calculated from self-reported food records based on Nutrition Data System for Research (NDS-R).
Presented is the average daily energy intake (kcal/day).
|
3-5 days
|
|
Nutirion Intake: Carbohydrate
Prazo: 3-5 days
|
Data were collected through food journals.
Energy and macronutrient composition were calculated from self-reported food records based on Nutrition Data System for Research (NDS-R).
Presented is the average daily carbohydrate intake (g/day).
|
3-5 days
|
|
Nutirion Intake: Fat
Prazo: 3-5 days
|
Data were collected through food journals.
Energy and macronutrient composition were calculated from self-reported food records based on Nutrition Data System for Research (NDS-R).
Presented is the average daily fat intake (g/day).
|
3-5 days
|
|
Nutirion Intake: Protein
Prazo: 3-5 days
|
Data were collected through food journals.
Energy and macronutrient composition were calculated from self-reported food records based on Nutrition Data System for Research (NDS-R).
Presented is the average daily protein intake (g/day).
|
3-5 days
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Investigadores
- Investigador principal: Renata Belfort De Aguiar, MD, PhD, Yale School of Medicine
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Real)
1 de fevereiro de 2016
Conclusão Primária (Real)
14 de dezembro de 2017
Conclusão do estudo (Real)
14 de dezembro de 2017
Datas de inscrição no estudo
Enviado pela primeira vez
1 de fevereiro de 2016
Enviado pela primeira vez que atendeu aos critérios de CQ
2 de fevereiro de 2016
Primeira postagem (Estimativa)
3 de fevereiro de 2016
Atualizações de registro de estudo
Última Atualização Postada (Real)
5 de maio de 2022
Última atualização enviada que atendeu aos critérios de controle de qualidade
8 de abril de 2022
Última verificação
1 de abril de 2022
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- 1503015469
- 1K23DK098286-01A1 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
NÃO
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .